drugset / Trial / NCT00063258

Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

NCT00063258

Phase 2 Terminated 5 enrolled M.D. Anderson Cancer Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn about the safety and effectiveness of OSI-774 when combined with standard chemotherapy (carboplatin and paclitaxel) before surgery in the treatment of non-small cell lung cancer.

Timeline

Start
2003-06
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Erlotinib Small molecule 150 mg Oral
Comparator Carboplatin Small molecule 6 unknown
Comparator Paclitaxel Small molecule 200 mg/m2 Intravenous

Indications